The BEACON2 selection is a significant non-dilutive validation of elraglusib's neuroblastoma potential, but Actuate faces a near-term cash runway risk beyond July 2026. Traders should monitor for financing announcements and early BEACON2 data readouts. The Rare Pediatric Disease designation adds potential upside via a priority review voucher.
Price Chart
Executive Summary
Actuate Therapeutics announced that its lead drug elraglusib will be evaluated in the BEACON2 platform trial for relapsed/refractory neuroblastoma, a rare pediatric cancer. The trial is sponsored by Cancer Research UK, providing capital-efficient data generation. A complete response was previously observed in a neuroblastoma patient in a Phase 1 study, and elraglusib holds FDA Rare Pediatric Disease designation, which may provide a path to priority review and a potential voucher.
Key Facts
- Elraglusib selected for BEACON2, a European multi-arm Phase 1/2 platform trial for relapsed/refractory neuroblastoma, sponsored by Cancer Research UK Clinical Trials Unit.
- Dose confirmation cohort of up to 20 patients; may advance to randomized portion with ~75 patients and planned interim analysis.
- A heavily pretreated neuroblastoma patient achieved a complete bone marrow response within 9 cycles in a prior Phase 1/2 study (NCT04239092).
- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma, which can qualify for a priority review voucher upon approval.
- Preclinical data showed 60% of Th-MYCN mice treated with elraglusib plus TEMIRI/14G2a remained tumor-free at one year vs. 0% in the control arm (P<0.0001).
- Actuate is a clinical-stage company with a going concern risk; it requires additional capital to fund operations beyond July 2026.
Financial Impact
No financial terms disclosed; trial is sponsored by Cancer Research UK, reducing Actuate's cost burden. Potential value of a Rare Pediatric Disease priority review voucher is substantial but uncertain.
Risk Factors
- Actuate has a going concern risk and requires additional capital beyond July 2026; failure to raise funds could delay or terminate development.
- BEACON2 is early-stage (dose confirmation cohort of 20 patients); clinical failure or safety issues could derail the program.
- Neuroblastoma is a rare disease with limited commercial opportunity; even if successful, peak sales may be modest.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308735 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.5279 (+11.87%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.5279 (−21.58%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.5279 (+27.09%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.5279 (+45.57%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.5279 (−73.74%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.5279 (−81.73%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5279 (−82.34%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5279 (−82.34%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.5279 (−74.62%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.5279 (−82.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers